Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane by Marijke Linschoten, Jesse Geels, Erik van Werkhoven, Heleen Visser-Wisselaar, Martine E. D. Chamuleau, Arco J. Teske, Lourens Robbers, Simone Oerlemans, Heleen Crommelin, Marleen Breems-de Ridder, Astrid Schut, Folkert W. Asselbergs, Anna van Rhenen, on behalf of the HOVON 170 DLBCL – ANTICIPATE consortium

Subjects: “…Diffuse large B-Cell lymphoma…”
Get full text

Interactive Visualization for Patient-to-Patient Comparison by Quang Vinh Nguyen, Guy Nelmes, Mao Lin Huang, Simeon Simoff, Daniel Catchpoole

Subjects: “…precursor cell lymphoblastic leukemia-lymphoma…”
Get full text

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial by Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu, Zhi-Ming Li

Subjects: “…Diffuse large B-cell lymphoma…”
Get full text

The Influence of Gastric Microbiota and Probiotics in <i>Helicobacter pylori</i> Infection and Associated Diseases by Jagriti Verma, Md Tanveer Anwar, Bodo Linz, Steffen Backert, Suneesh Kumar Pachathundikandi

Subjects: Get full text

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration by Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík

Subjects: “…relapsed/refractory large B‐cell lymphoma…”
Get full text

Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma by Rui Zhang, Yi Zhang, Hairong Xiao, Qingxi Liu, Mingfeng Zhao

“…The combination of PD-1 inhibitors and CAR-T has shown encouraging results in treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, there are still cases where treatment is ineffective. …”
Get full text

Lymphoid Infiltrates in B Cell Non Hodgkin’s Lymphoma: Comparing Nuclear Characteristics between Lymph Node and Bone Marrow; and Evaluating Diagnostic Features of Bone Marrow Infiltrates in Paraffin Embedded Tissues by Mark H. Deverell, Elizabeth Best, Jonathan R. Salisbury

“…Distinguishing non Hodgkin’s lymphoma from benign lymphoid aggregates in bone marrow is well recognised to be difficult. …”
Get full text

Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion by Runhui Zheng, Xiaobo Chen, Chunyan Wang, Pengfei Qin, Huo Tan, Xiaodan Luo

“…Double-expressor diffuse large B-cell lymphoma (DLBCL) with 17p deletion is an aggressive and refractory disease. …”
Get full text

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma by Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Alessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani

Get full text

Multiple Myeloma and B Cell Lymphoma. Investigation of IL-6, IL-6 Receptor Antagonist (IL-6RA), and GP130 Antagonist (GP130A) Using Various Parameters in an In Vitro Model by Eva Kovacs

“…This kind of therapy is not recommended for B cell lymphoma, as these cells have no IL-6R.…”
Get full text

Transformation of Undifferentiated Thy-1lo B220+ Thymic Lymphoid Cells by the Abelson Murine Leukemia Virus by Eric Y. Chen, Bradley J. Swanson, Steven S. Clark

Subjects: Get full text

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors by Russell J. Schilder, Drew Rasco, Manish R. Sharma

Subjects: “…Anaplastic lymphoma kinase (ALK)…”
Get full text

Cost drivers associated with autologous stem-cell transplant (ASCT) in patients with relapsed/refractory diffuse large B-cell lymphoma in a Japanese real-world setting: A structural equation model (SEM) analysis 2012-2022. by Saaya Tsutsué, Shinichi Makita, Hiroya Asou, Shingo Wada, Wen Shi Lee, Dilinuer Ainiwaer, Koki Idehara, Sona-Sanae Aoyagi, Seok-Won Kim, Todd Taylor

“…Diffuse large B-cell lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma, with increasing incidence, in Japan. …”
Get full text

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada by Lara Chayab, Natasha B. Leighl, Mina Tadrous, Christine M. Warren, William W. L. Wong

Get full text

Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model by Lin Yang, Ting Chen, Qiuling Zhao, Liangliang Dong, Wanfu Zhong, Wenbin Liu, Xiuliang Qiu, Ruyi Huang, Shengqiang Huang, Ruixiang Xie

“…Objective To evaluate the cost-effectiveness of polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in China.Design A Markov model was constructed to analyse the cost-effectiveness of two strategies in CD20-positive patients with previously untreated DLBCL over a lifetime horizon: (1) pola-R-CHP and (2) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). …”
Get full text

The cancer-associated fibroblasts interact with malignant T cells in mycosis fungoides and promote the disease progression by Yige Zhao, Yong Li, Yong Li, Panpan Wang, Mengyan Zhu, Jiaqi Wang, Bo Xie, Chenyu Tang, Yangyang Ma, Shiwen Wang, Sha Jin, Jinhui Xu, Zhao Li, Xiaoyan Zhang, Liuyu Li, Xiuzu Song, Ping Wang

Subjects: Get full text

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, follo... by G. Menardi, A. Castellino, C. Castellino, M. E. Bersia, E. Grande, G. Fraternali, M. Massaia, C. Fruttero

Subjects: Get full text

Awardee Summary of 2023 Taiwan Oncology Society Clinical Research Award Recipient: Persistent Endeavors on Research of Digestive Cancers for Three Decades by Kun-Huei Yeh

Subjects: “…gastric mucosa-associated lymphoid tissue lymphoma…”
Get full text

Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Co... by V. T. Ivashkin, T. L. Lapina, I. V. Maev, O. M. Drapkina, R. S. Kozlov, A. A. Sheptulin, A. S. Trukhmanov, S. R. Abdulkhakov, O. P. Alekseeva, S. A. Alekseenko, D. N. Andreev, D. S. Bordin, N. N. Dekhnich, I. L. Klyaritskaya, N. V. Korochanskaya, M. F. Osipenko, E. A. Poluektova, A. S. Sarsenbaeva, V. I. Simanenkov, A. V. Tkachev, A. I. Ulyanin, I. B. Khlynov, V. V. Tsukanov

Subjects: Get full text

Adverse events in the nervous system associated with blinatumomab: a real-world study by Wen Gao, Jingwei Yu, Yifei Sun, Zheng Song, Xia Liu, Xue Han, Lanfan Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang

Get full text